Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
Condition: Ovarian Cancer
MeSH terms: Ovarian Neoplasms; Carcinoma, Ovarian Epithelial
Intervention: Docetaxel; Carboplatin; Pegylated G-CSF
Intervention MeSH terms: Carboplatin; Docetaxel
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 18.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      In this study the investigators will be using an AUC of 6 based on creatinine clearance using
      the Carboplatin dosing formula used for Gynecologic Oncology Group protocols.

      Given that myelosuppression was significant using the docetaxel dose of 75 mg/m*2 in the
      SCOTROC trial, the prophylactic use of pegylated G-CSF in this Phase II trial is warranted.
      The expectation would be that patients will be able to receive their cycles in a more timely
      fashion, with less delays, thereby allowing for improved outcomes and decreased
      hospitalizations due to myelosuppression.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed newly diagnosed Stage III/IV epithelial ovarian or primary
             peritoneal carcinoma at time of initial diagnosis

          -  Treatment must start within 8 weeks of surgery

          -  Subjects may be measurable per RECIST criteria or evaluable for disease response by
             CA125. Evaluable CA 125 levels are defined as an elevated CA125 pre operatively which
             either remains elevated post-operatively or normalizes after surgery

          -  No prior chemotherapy or radiation therapy

          -  Age ≥ 18

          -  Performance Status must be ≤ 2 (ECOG)

          -  Peripheral neuropathy: must be ≤ grade 1

          -  Hematologic (minimal values)

               -  Absolute neutrophil count ≥ 1,500/mm3

               -  Hemoglobin ≥ 8.0 g/dl

               -  Platelet count ≥ 100,000/mm3

          -  Hepatic

             *Total Bilirubin ≤ ULN

          -  AST and ALT and Alkaline Phosphatase must be within the range allowing for
             eligibility.

               -  If alkaline phosphatase is ≤ ULN and AST or ALT is >5x ULN then the patient is
                  not eligible

               -  If alkaline phosphatase is >1x but ≤2.5 x the ULN and the AST or ALT is >1.5x the
                  ULN then the patient is not eligible

               -  If alkaline phosphatase is >2.5x but ≤5x the ULN and the AST or ALT is >1x the
                  ULN then the patient is not eligible

               -  If alkaline phosphatase is >5x the ULN then the patient is not eligible

          -  Renal: Creatinine (serum) less than or equal to 1.5 ULN, CTC grade 1.

          -  Women of childbearing potential must have a negative pregnancy test and must be
             willing to consent to using effective contraception while on treatment and for at
             least 3 months thereafter.

        PT/PTT ≤ 1.5 x's ULN

        Exclusion Criteria:

          -  Patients with a history of severe hypersensitivity reaction to Docetaxel or other
             drugs formulated with polysorbate 80.

          -  Women who are pregnant or breast-feeding.

          -  Patients who have signs of infection or who have not recovered from the effects of
             recent surgery

          -  Patients with a performance status of 3 or 4

          -  Patients with a second malignancy within past 5 years other than non-melanoma skin
             carcinoma.

          -  Patients who have received prior myelosuppressive chemotherapy or XRT.